Product Description
BLU-782 is being developed by Blueprint Medicines for the treatment of patietns with fibrodysplasia ossificans progressiva (FOP). (Sourced from: https://www.blueprintmedicines.com/wp-content/uploads/2019/09/Blueprint-Medicines-ASBMR-2019-BLU-782-Poster1.pdf)
Mechanisms of Action: ALK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Blueprint Medicines
Company Location: CAMBRIDGE MA 02139
Company CEO: Kathryn Haviland
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BLU-782-0101 | P1 |
Completed |
Healthy Volunteers |
2019-09-11 |
28% |